09.03.2020 • News

DuPont Buys Lodestone Partners

DuPont Buys Lodestone Partners
DuPont Buys Lodestone Partners

DuPont Sustainable Solutions (DSS) has acquired the assets of Lodestone Partners, a Canadian consultancy focused on improving operating performance at companies in the natural resource and mining industry. Financial terms of the deal, which was effective as of Feb. 29, were not disclosed.

DSS said the acquisition gives it expanded capability, deep experience and proven methodologies in operations excellence.

“Combining Lodestone’s highly respected operational improvement expertise with DSS’ risk management capabilities will now enable us to deliver an integrated operations transformation capability that is not currently available in the marketplace,” said Davide Vassallo, CEO of DSS. “This acquisition significantly expands DSS’ ability to help our clients protect their people and improve operations and is a significant step forward in our strategy to accelerate growth in select geographies and industries since becoming an independent company in September,” he said

Robin Schleich, former director of Lodestone Partners, added that DSS has “incredibly strong capabilities in operations risk management, capability development, data analytics and digital technology integration.”  Following the takeover, Schleich is now director for operations excellence practice within DSS.

The addition of Lodestone means that DSS now has more than 900 consultants operating out of 40 offices worldwide.

DSS was part of DowDuPont Specialty Products before it became independent in February 2019, retaining its existing management and supported by Swiss investment group Gyrus Capital. The company provides consultancy services to the oil & gas, chemicals/petrochemicals, mining and metals, and manufacturing industries.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read